Posts tagged ‘biotech’
April 20th, 2011
Pieter Droppert in a previous position worked as a Global Project Director for a phase II Alzheimer’s clinical trial program in emerging markets. He maintains an interest in this area and the new products in drug development.
In a new post on Biotech Strategy Blog, Pieter writes about research published in the journal Neurology that showed magnetic resonance imaging (MRI) could detect pre-symptomatic Alzheimer’s disease (AD).
Brad Dickerson and colleagues from Mass General and Rush University in Chicago looked at two groups of subjects who were cognitively normal, and then over time investigated the brain differences seen in those patients who developed AD.
Their conclusion is that changes in cortical thickness are a biomarker for AD, in other words structural brain changes can be seen before they develop clinical symptoms.
This research is still very early and has a number of limitations, including the low sample size and the need for computer power to do the analysis.
That said, the promise of all the biomarkers under development to diagnose early stage AD, whether they be amyloid imaging of plaque through PET scans or via MRI, is they offer the hope of being able to detect those patients at risk before the brain becomes irreparable.
By the time clinical symptoms of dementia or mild cognitive impairment manifests itself, then it’s likely the damage has already been done, and the brain has been snagged or disrupted by the disease in a way that is hard to reverse.
Early detection of those individuals at risk allows the prospect of using neuroprotective drugs to delay the onset of clinical symptoms.
Recognition of the importance of preclinical diagnosis i.e. before symptoms develop was also shown by the announcement yesterday by the National Institute on Aging, a branch of the NIH – National Institutes on Health of new diagnostic guidelines for Alzheimer’s patients.
These guidelines divide patients into three diagnostic groups: preclinical, mild cognitive impairment (MCI) and dementia. The preclinical group is completely new and a recognition that structural and molecular changes occur in the brain before clinical symptoms manifest themselves.
There is considerable research into AD biomarkers to suggest that in the next 5 years we will be able to detect those people at risk, but the challenge remains in developing new drugs that slow down or reverse the onset of the neuronal tangling that occurs.
AD is a disease that will touch many families as the population in many countries becomes older. If you are interested in this area, you can read more on Biotech Strategy Blog.
February 8th, 2011
While at Quintiles, Pieter Droppert was a lead CRA and European project manager for risedronate clinical trials, and he has since maintained an interest in osteoporosis new product development.
On the Biotech Strategy Blog, he discusses a recent review published in Nature Reviews Drug Discovery on the emerging treatments in development for osteoporosis. He comments on some of the barriers to market entry that companies will increasingly face such as pressure not to do placebo-controlled trials with high fracture-risk subjects.
For further commentary and insight on the osteoporosis market, read the full post on Biotech Strategy Blog.
New research points to role of Cystic Fibrosis Transmembrane Conductance Regulator Signaling in Emphysema
January 10th, 2011
January 4th, 2011
Sally Church, PhD will be attending the 6th International Society of Gastroenterological Carcinogenesis (ISGC) meeting in Houston from Thursday 6th to Saturday, 8th January, 2011. Hosted by the MD Anderson Cancer Center, the meeting has an impressive line up of key opinion leaders. Further information can be found on the Pharma Strategy Blog.
December 29th, 2010
Published by Sally Church on Pharma Strategy Blog
December 27th, 2010
December 21st, 2010
December 18th, 2010
Icarus Consultants would like to wish all our clients, friends and colleagues around the world a happy, healthy and prosperous New Year. Puisse la nouvelle année vous apporter paix, bonheur et prospérité.
This year we made a donation to GRACE, Global Resource for Cancer Education instead of mailing greeting cards.
Our office will close on Friday, December 24 2010 and reopen for business on Monday, January 3, 2011.